Pharmaceuticals & Therapeutics

With $60M in new funding and veteran pharma execs on board, Vedanta Biosciences is set for the pivotal last leg of its Phase 3 trial for VE303.

A new partnership between Japan's Ono Pharma and US biotech Mediar aims to disrupt the massive fibro-inflammatory disease market by targeting the root cell of scarring.

Priovant's Phase 3 trial for brepocitinib in cutaneous sarcoidosis isn't just about one disease. It's a key move in Roivant's playbook to build a rare disease powerhouse.

With nearly $800M in cash, Immunovant is all-in on a single drug, IMVT-1402. Can its ambitious six-front clinical strategy justify the burn and win the race?

Actimed Therapeutics reclaims S-oxprenolol, a promising ALS drug. This isn't just a pipeline shuffle; it's a calculated move to dominate the future of muscle health.

With a pill aimed at both heart disease and blindness, BioAge Labs is betting its future on fighting aging itself. Is this the dawn of a new era in medicine?

As Biofrontera preps its Q2 report, investors weigh record revenue and expanded margins against persistent losses and a critical need for cash flow breakeven.

Expedition Therapeutics lands a huge Series B and starts a pivotal trial for a drug that could finally target the root cause of COPD for millions.

Eton Pharmaceuticals' new deal for ASN-001 is more than a pipeline buy; it's a calculated maneuver to capture the entire infantile hemangioma treatment space.

A revenue dip masks a calculated pivot. UTHR is betting its future not just on new drugs, but on a revolutionary plan to manufacture human organs.

Compass Pathways is racing towards a 2027 launch for its psilocybin therapy. But can it navigate the complex regulatory and commercial hurdles to deliver on its promise?

As Everest Medicines preps its H1 2026 results, investors are watching for more than just profit, focusing on its pivot to a global innovation engine.

Entropy Neurodynamics launches a world-first 'basket study' for its IV psilocin, a high-stakes bet that could redefine mental health treatment pipelines.

A new oral tablet from Entera Bio could replace painful daily injections for millions with severe osteoporosis, a move validated by a top scientific conference.

Healis Therapeutics gets FDA nod for Tyemvers, a botulinum toxin therapy for depression. Can a drug that paralyzes frown muscles disrupt mental healthcare?

Vantage Biosciences has completed enrollment for its oral drug, oruvestat, a potential game-changer for early diabetic retinopathy. This could replace invasive injections.

A positive safety review for Molecure's novel sarcoidosis drug OATD-01 de-risks its development, offering new hope for patients and boosting the company's strategic value.

Exicure is settling a $1M debt with stock, a move to preserve its dwindling cash. Can this gamble save its new focus on blood cancer therapy or just delay the inevitable?

Ceruvia Lifesciences secures $8M for a non-hallucinogenic LSD analog to treat cluster headaches, offering a potential breakthrough for a severe pain disorder.

Amidst the fallout of its CEO's ouster, Anavex Life Sciences unveils a new board slate to fend off an activist investor's bid for total control.